• +1-646-491-9876
    • +91-20-67278686

    Search

    Leukocyte Surface Antigen CD47 Pipeline Review H1 2017

    Leukocyte Surface Antigen CD47 Pipeline Review H1 2017

    • Report Code ID: RW0001851079
    • Category Life Sciences
    • No. of Pages 61
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017

    Summary

    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47 - Pipeline Review, H1 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity) . It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Hodgkin Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Multiple Myeloma (Kahler Disease) , Myelodysplastic Syndrome, Atherosclerosis, B-Cell Non-Hodgkin Lymphoma, Bacterial Infections, Chronic Lymphocytic Leukemia (CLL) , Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Ischemia Reperfusion Injury, Kidney Transplant Rejection, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Mycosis Fungoides, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Small-Cell Lung Cancer and T-Cell Lymphomas.

    Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
    - The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
    Aurigene Discovery Technologies Ltd
    Celgene Corp
    Forty Seven Inc
    Surface Oncology Inc
    Trillium Therapeutics Inc
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
    ALX-148 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    B-6H12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-90002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hu-5F9G4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PSTx-23 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CD47 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRF-231 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tigecycline - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-621 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTI-622 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones
    Featured News & Press Releases
    Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade
    May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting
    Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
    Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients
    Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update
    Mar 31, 2017: Aurigene to Present Data on CD47-SIRPÎ interaction program at the AACR 2017
    Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621
    Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial
    Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-621
    Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622
    Jan 31, 2017: Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
    Dec 15, 2016: Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer
    Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
    Dec 02, 2016: Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models
    Nov 29, 2016: Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
    Pipeline by Celgene Corp, H1 2017
    Pipeline by Forty Seven Inc, H1 2017
    Pipeline by Surface Oncology Inc, H1 2017
    Pipeline by Trillium Therapeutics Inc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aurigene Discovery Technologies Ltd
    Celgene Corp
    Forty Seven Inc
    Surface Oncology Inc
    Trillium Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//leukocyte-surface-antigen-cd47-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//leukocyte-surface-antigen-cd47-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//leukocyte-surface-antigen-cd47-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments